Trial testing oral med for 2 Batten types now recruiting kids at first US site

Boys Town enrolling children ages 2-15; 5 more centers expected in new year

Written by Marisa Horak, MS |

A medical team in scrubs, including one clinician holding a vial of blood, is shown meeting around a large table.

A new clinical trial will evaluate the oral treatment candidate PLX-200 in children with both juvenile Batten disease and late infantile Batten disease. (Image from iStock)

A basket trial — a clinical study testing a single drug across multiple diseases — will evaluate the oral treatment candidate PLX-200, originally developed as a cholesterol-lowering drug, in children with both juvenile Batten disease, also known as CLN3 disease, and late infantile Batten disease, also called CLN2 disease.

Launched by Polaryx Therapeutics, the trial is now recruiting children ages 2 through 15 at its first study site: Boys Town National Research Hospital in Nebraska.

Polaryx, the biotech company developing PLX-200 and sponsoring the Phase 2 trial, announced that this location has been activated for pediatric patients with these two Batten types, as well as for youngsters with two other neurological conditions. The trial will expand next year to five additional sites across the U.S., which are expected to begin screening participants in early 2027, according to a company press release. Boys Town is a village just west of Omaha, located in the eastern part of the state.

“For a study addressing several ultra-rare pediatric diseases, each participating center plays a meaningful role in identifying eligible patients and supporting families throughout the trial. We are pleased to begin this next phase with the experienced team at Boys Town as we work toward our first patient dosing milestone,” said Alex Yang, chair and CEO of Polaryx.

Recommended Reading
An illustration shows white blood cells on a red background.

Umbilical cord blood transplant possible in Batten children: Study

The Boys Town hospital provides care to children with a range of rare neurological conditions, and is an affiliate center in the Batten Disease Support, Research, and Advocacy (BDSRA) Foundation‘s Batten Disease Clinical Center of Excellence Program.

According to Will Charlton, MD, chief medical officer of Polaryx, “Boys Town brings specialized expertise in pediatric neurology and rare genetic diseases, along with close relationships across the Batten disease community.”

Developer also seeking to open trial sites in Europe

Polaryx said it has also submitted applications to regulatory authorities in the U.K. and the European Union, seeking the go-ahead to open study sites in Europe as well.

“With the first site activated, our immediate focus is on protocol-based screening and enrollment while continuing to prepare additional sites,” Charlton said. He added: “We are grateful for the commitment of the investigators, clinical teams and families who make rare disease research possible.”

The SOTERIA (NCT07740512) site at Boys Town is being led by Isabella Herman, MD, PhD, a pediatric neurologist and neurogeneticist.

“We are incredibly proud to be the first site activated for this trial, bringing innovative research closer to the families who need it most,” Herman said.

The drug’s developer is aiming to repurpose PLX-200 to treat both juvenile and late infantile Batten disease. Each is a lysosomal storage disorder, which is a genetic condition that disrupts the activity of a cellular compartment called the lysosome.

The lysosome normally acts like a biological garbage disposal, breaking down molecular waste into simple components that the cell can repurpose. In people with these disorders, this disposal system isn’t able to adequately break down certain types of molecular waste, meaning these molecules build up to toxic levels in cells and ultimately drive disease symptoms.

Recommended Reading
Main graphic for Cristina Vargas' column,

The importance of spreading awareness about Batten disease

Trial’s main goal is testing safety of Batten treatment candidate

PLX-200 is an oral small molecule that’s been repurposed as a potential treatment for lysosomal storage disorders because it can enter the brain and promote the formation of new lysosomes in cells, called lysosomal biogenesis. In addition to the two types of Batten disease, the study is also open to children with Krabbe disease and Sandhoff disease, two other types of lysosomal storage disorders.

All participants in SOTERIA will receive PLX-200, and the study’s primary goal is to assess the safety and tolerability of the experimental therapy.

For patients living with CLN2 and CLN3 Batten disease, … the need for effective treatments is urgent.

According to Polaryx, data from patients with the two Batten disease types will also be compared with natural history studies — ones that track the evolution of the disease without treatment. Such comparisons will help inform future development plans, per the company.

“As a pediatric neurogeneticist specializing in precision medicine, I have witnessed firsthand the devastating impact that rare neurodegenerative diseases have on children and their families,” Herman said. “For patients living with CLN2 and CLN3 Batten disease, Krabbe disease, and Sandhoff disease, the need for effective treatments is urgent.”

Herman said the trial “represents an important opportunity to explore a potential disease-modifying therapy that could one day help preserve function, slow disease progression, and give families more meaningful time together.” The researcher added: “Initiatives like SOTERIA reflect our commitment to turning advances in precision medicine into meaningful hope for patients and families.”

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.